Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
TNBC-MERIT trial: what clinicians have said so far
RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID
- NCT02316457 ↗
- Completed
- BioNTech SE
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on TNBC-MERIT yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TNBC-MERIT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumor Therapy in Triple Negative Breast Cancer Patients
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Interventions
- IVAC_W_bre1_uID; IVAC_W_bre1_uID/IVAC_M_uID
- Arms
- ARM1 IVAC_W_bre1_uID · Experimental
- ARM2 IVAC_W_bre1_uID/IVAC_M_uID · Experimental
- ARM3 IVAC_W_bre1_uID + RBLTet.1 · Experimental
- Enrollment
- 42
- Primary outcomes
- Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID
- Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID plus IVAC_M_uID
- Sponsor
- BioNTech SE with Seventh Framework Programme
- Start
- Oct 2016
- Primary completion
- May 13, 2020
- Results posted
- No
- Registry record
- NCT02316457 · updated Mar 13, 2026
Publications
linked from the registry- Sahin U, Schmidt M, Derhovanessian E, Cortini A, Vogler I, Omokoko T, Godehardt E, Attig S, Newrzela S, Grutzner J, Bidmon N, Bolte S, Brachtendorf S, Stuhlmann T, Langer D, Brune D, Blake J, Feldner A, Lindman H, Schneeweiss A, Eichbaum M, Tureci O. Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC. Nature. 2026 Mar;651(8107):1088-1096. doi: 10.1038/s41586-025-10004-2. Epub 2026 Feb 18. PubMed 41708868